Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of VEGFA. The page also collects GeneMedi's different modalities and formats products for VEGFA in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the VEGFA target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Secreted Protein/Potential Cytokines.

This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]

Target IDGM-T20761
Target NameVEGFA
Gene ID7422
Gene Official NameVEGFA
Gene AliasMVCD1, VEGF, VPF
Protein Sub-locationSecreted Protein/Potential Cytokines
CategoryTherapeutics Target, Diagnostics Biomarker, INN Index, Cytokine Target, Immuno-oncology Target


Pre-made VEGFA-specific INN-index biosimilar (antibody&conjugates)-Vanucizumab, bevacizumab beta, conbercept, efdamrofusp alfa, aflibercept, abicipar pegol, Navicixizumab, Dilpacimab, Bevacizumab, tarcocimab, Brolucizumab, Ranibizumab, Tarcolimab, Varisacumab, Faricimab, Ivonescimab

Anti-VEGFA therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-ab-612Pre-Made Vanucizumab biosimilar, Bispecific mAb, Anti-ANGPT2;VEGFA Antibody: Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 therapeutic antibodyVanucizumabANGPT2;VEGFABispecific mAbINN mab
GMP-Bios-INN-757Pre-Made Bevacizumab Beta Biosimilar, Whole Mab, Anti-Vegfa Antibody: Anti-MVCD1/VEGF/VPF therapeutic antibodybevacizumab betaVEGFAWhole  mAbINN mab
GMP-Bios-INN-787Pre-Made Conbercept Biosimilar, Fusion Protein targeting VEGFA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting MVCD1/VEGF/VPFconberceptVEGFAFusion ProteinINN mab
GMP-Bios-INN-813Pre-Made Efdamrofusp Alfa P Alfaiosimilar, Bispecific, Anti-C3/CO3;C4B;VEGFA Antibody: Anti-AHUS5/ARMD9/ASP/CPAMD1/HEL-S-62p;CH/C4F/CO4/C4BD/C4B12/CPAMD3;VPF/MVCD1 therapeutic antibodyefdamrofusp alfaC3/CO3;C4B;VEGFABispecificINN mab
GMP-Bios-INN-722Pre-Made Aflibercept Biosimilar, Fusion Protein targeting VEGFA fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting MVCD1/VEGF/VPFafliberceptVEGFAFusion ProteinINN mab
GMP-Bios-INN-714abicipar pegolVEGFApegylatedINN mab
GMP-Bios-ab-369Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibodyNavicixizumabDLL4;VEGFABispecific mAbINN mab
GMP-Bios-ab-145Pre-Made Dilpacimab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibodyDilpacimabDLL4;VEGFABispecific mAbINN mab
GMP-Bios-ab-065Pre-Made Bevacizumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibodyBevacizumabVEGFAWhole mAbINN mab
GMP-Bios-INN-1009Pre-Made Tarcocimab Biosimilar, Whole Mab, Anti-Vegfa Antibody: Anti-MVCD1/VEGF/VPF therapeutic antibodytarcocimabVEGFAWhole  mAbINN mab
GMP-Bios-ab-083Pre-Made Brolucizumab biosimilar, scFv, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibodyBrolucizumabVEGFAscFvINN mab
GMP-Bios-ab-470Pre-Made Ranibizumab biosimilar, Fab, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibodyRanibizumabVEGFAFabINN mab
GMP-Bios-ab-700Pre-Made Tarcolimab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibodyTarcolimabVEGFAWhole mAbINN mab
GMP-Bios-ab-613Pre-Made Varisacumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibodyVarisacumabVEGFAWhole mAbINN mab
GMP-Bios-ab-204Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibodyFaricimabVEGFA;ANGPT2Bispecific mAbINN mab
GMP-Bios-ab-674Pre-Made Ivonescimab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibodyIvonescimabVEGFAscFv-IGHCINN mab



Pre-made anti-VEGFA inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-VEGFA benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-VEGFA mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T20761-AbAnti-VEGFA monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibody, Diagnostic target antibody, Cytokine antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×